Elanco Animal Health (ELAN)

Overall impact
C (59)

Commentary

Elanco Animal Health is an average overall performer. With a 'C' rating of 58.7 for overall impact (60th percentile compared to all companies), Elanco Animal Health ranks 116th out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 112 others, and ahead of Evolus, Oyster Point Pharma, Lupin and 35 others. On top material causes for Elanco Animal Health's industry (Pharmaceuticals & Biotech), Elanco Animal Health performs well in Child and Maternal Health (92.2 score), Child and Maternal Health (93.0), Child and Maternal Health (95.4) and 4 other causes where it received an 'A' score and performs poorly in Reduced Waste (25.6 score), Racial Justice and Civil Rights (36.7), Sustainable Use of Natural Resources (32.0) and 3 other causes where it received a 'D' or 'F' score.
Impact
Cause ELAN
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
9,400
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
In, United States
Share classes
ELAN
Mission
Enriching lives through food and companionship by developing innovative solutions that protect & enhance animal health.
Description
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks. The company provides prescription parasiticide products and over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks. It also has a vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks, and a therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. In addition, Elanco offers farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. It provides medicated feed additives, injectable antibiotics, vaccines, insecticides, and enzymes under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Furthermore, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax trademarks. Elanco sells its products to third-party distributors and independent retailers, and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Material causes
Ethos considers the following causes material for Elanco Animal Health, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.